Validated high‐performance liquid chromatography method for the determination of the inhibitor of cancer cell invasion ( E )‐ N ‐benzyl‐6‐[2‐(3, 4‐dihydroxy benzylidene)hydrazinyl]‐ N ‐methylpyridine‐3‐sulfonamide in rat plasma and its application to pharmacokinetic study

In this study, a reliable method for the quantitation of ( E )‐ N ‐benzyl‐6‐[2‐(3, 4‐dihydroxy benzylidene)hydrazinyl]‐ N ‐methylpyridine‐3‐sulfonamide (JW‐55) in rat plasma was developed and validated using high‐performance liquid chromatography. Plasma samples were deproteinized; sildenafil was used as an internal standard. Chromatographic separation was achieved using a reversed‐phase C 18 column. The mobile phase, 0.02  m ammonium acetate buffer:acetonitrile (48:52, v /v), was run at a flow rate of 1.0 mL/min at room temperature, and the column eluent was monitored using an ultraviolet detector at 280 nm. The retention times of JW‐55 and sildenafil were ~5.9 and 7.7 min, respectively. The detection limit of JW‐55 in rat plasma was 0.03 μg/mL. Pharmacokinetic parameters of JW‐55 were evaluated after intravenous and oral administration of JW‐55 (10 mg/kg) in rats. After oral administration, the F value was approximately 73.7%.